lacutamab (IPH4102) / Innate 
Welcome,         Profile    Billing    Logout  
 3 Diseases   3 Trials   3 Trials   127 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lacutamab (IPH4102) / Innate
2020-003735-16: A STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Not yet recruiting
2
56
Europe
Lacutamab, IPH4102, Solution for infusion
LYSARC, Innate Pharma
Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy, Relapsed/refractory patients with peripheral T-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
KILT, NCT04984837: Study of Lacutamab in Peripheral T-cell Lymphoma

Checkmark KIR3DL2-expressing patients with r/r PTCL
Aug 2021 - Aug 2021: KIR3DL2-expressing patients with r/r PTCL
Recruiting
2
56
Europe
Lacutamab, Gemcitabine, Oxaliplatine
The Lymphoma Academic Research Organisation, Innate Pharma
Peripheral T Cell Lymphoma, Relapse/Recurrence
01/26
01/28
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lacutamab (IPH4102) / Innate
2020-003735-16: A STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Not yet recruiting
2
56
Europe
Lacutamab, IPH4102, Solution for infusion
LYSARC, Innate Pharma
Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy, Relapsed/refractory patients with peripheral T-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
KILT, NCT04984837: Study of Lacutamab in Peripheral T-cell Lymphoma

Checkmark KIR3DL2-expressing patients with r/r PTCL
Aug 2021 - Aug 2021: KIR3DL2-expressing patients with r/r PTCL
Recruiting
2
56
Europe
Lacutamab, Gemcitabine, Oxaliplatine
The Lymphoma Academic Research Organisation, Innate Pharma
Peripheral T Cell Lymphoma, Relapse/Recurrence
01/26
01/28
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24

Download Options